Detoxification enzyme polymorphisms as risk factors fo t-AML

Maria Teresa Voso; Francesco D’Alò; Giuseppe Leone

doi:10.4081/hmr.v2i15.604

Abstracts

16 June 2009

Vol. 2 No. 15 (2006)

https://doi.org/10.4081/hmr.v2i15.604

Detoxification enzyme polymorphisms as risk factors fo t-AML

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

273

Views

329

Downloads

Authors

Maria Teresa Voso

support@pagepress.org

Francesco D’Alò

Giuseppe Leone

Todate, therapy-related myelodysplastic syndromes/acute Myeloid Leukemias (t-MDS/ AML) represent the main long-term adverse effect of cancer treatment. The identification of new prognostic factors has raised the question whether reducing treatment intensity in good prognosis patients may save them from long term-toxicity, without impairing response rates.